exelixis drug slows prostate cancer spread in trial
exelixis inc's cabozantinib experimental drug shrank bone malignancies from prostate cancer in 76 percent of patients, interim results from a midstage trial show.
http://feeds.reuters.com/~r/reuters/healthnews/~3/9exldecied8/us-exelixis-prostate-idustre7556iz20110606
5934
06 Jun 2011 23:42:03
reuters
health